To determine complete recanalization, early clinical recovery rates, and safety of continuous monitoring in patients treated with 2 Mhz transcranial Doppler (TCD) used in conjuction with tissue plasminogen activator (tPA) in patients with acute ischemic stroke.
- Tissue plasminogen activator (Activase®)Drug
Intervention Desc: Thrombolytic
Prospective, randomized, multi-center clinical trial.
All patients received a standard dose of tPA (0.9 mg/kg) with either 2 hours of TCD monitoring or placebo monitoring.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Complete recanalization within 2 hours, early or dramatic clinical recovery at 2 hours and 24 hours, intracerebral hemmorhage with clinical worsening.|
|Secondary||Clinical recovery at 24 hours as measured by NIHSS; favorable outcome at three months as measured by modified Rankin; and mortality at three months.|